September 28, 2022 Bryant Lim Haverford, PA 19041 Re: Employment Continuation and Retention Bonus Letter AgreementEmployment Continuation and Retention Bonus Letter Agreement • September 30th, 2022 • Idera Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
As you are aware, Idera Pharmaceuticals, Inc. (the “Company”) intends to enter into an Agreement and Plan of Merger by and among the Company, Aceragen, Inc. and certain other parties (the “Merger Agreement”). In addition, following the consummation of the transactions contemplated by the Merger Agreement (the “Closing”), the stockholders of the Company will vote to approve the Parent Stockholder Matters (as defined in the Merger Agreement) (the “Approval”). In recognition of your efforts in connection with the Closing and to encourage you to continue your high level of commitment to the Company through the Closing, the Approval, and thereafter, you are eligible to receive the payments set forth in this letter agreement, subject to the terms and conditions set forth herein.
